This concept note describes the methods used to assess the prevalence of any HIVDR and HIVDR by PMTCT exposure among children less than 18 months of age using remnant dried blood spot specimens from early infant diagnosis over a 12-month period
Data from the 2011 Ethiopia Demographic and Health Survey
DHS Working Papers No. 119
DHS Working Papers No. 85
Tinkhomba teHIV/AIDS letivetwa ngulolucwaningo lweTemphilo lwa 2006-07
DHS Working Papers No. 111 | Zimbabwe Working Papers No. 12
DHS Working Papers No. 110 | Zimbabwe Working Papers No. 11
This toolkit provides a variety of resources that will help you coordinate, design, develop, deliver, and evaluate training for HIV/AIDS healthcare providers.
O presente relatório descreve os resultados preliminares de indicadores de HIV, estimados no âmbito do Inquérito de Indicadores de Imunização, Malária e HIV/SIDA em Moçambique (IMASIDA 2015), conduzido pelo INS em colaboração com o INE.
O Inquérito de Indicadores de Imunização, Malári...a e HIV/SIDA foi realizado com o objectivo de determinar a prevalência do HIV e SIDA e malária, bem como outros indicadores de saúde da mulher e da criança no país.
more
This country profile provides an overview of latest available data on a variety of HIV related topics in Mozambique as of 2016.
HIV Prevalence: Data from the 2010 Rwanda Demographic and Health Survey.
DHS Working Papers No. 105 - Rwanda has developed and implemented many strategies at the national level to reduce the incidence of HIV in the general population. One of the main objectives of such interventions is to improve the general level of knowledge of HIV, with the hypothesis that increasing... HIV knowledge will reduce risky sexual behavior. However, there has been a concern that HIV knowledge may not necessarily reduce risky sexual behavior. Only a limited number of population-based studies describe the results of these interventions in terms of how HIV knowledge affects risky sexual behavior. Therefore, the aim of this paper is to fill in this gap, by exploring HIV knowledge and its effect on risky sexual behavior among men in Rwanda.
more
This report investigates the impact of potential misclassification of samples on HIV prevalence estimates for 23 surveys conducted from 2010-2014. In addition to visual inspection of laboratory results, we examined how accounting for potential misclassification of HIV status through Bayesian latent ...class models affected the prevalence estimates. Two types of Bayesian models were specified: a model that only uses the individual dichotomous test results and a continuous model that uses the quantitative information of the EIA (i.e., the signal-to-cutoff values). Overall, we found that adjusted prevalence estimates matched the surveys’ original results, with overlapping uncertainty intervals. This suggested that misclassification of HIV status should not affect the prevalence estimates in most surveys. However, our analyses suggested that two surveys may be problematic. The prevalence could have been overestimated in the Uganda AIDS Indicator Survey 2011 and the Zambia Demographic and Health Survey 2013-14, although the magnitude of overestimation remains difficult to ascertain. Interpreting results from the Uganda survey is difficult because of the lack of internal quality control and potential violation of the multivariate normality assumption of the continuous Bayesian latent class model. In conclusion, despite the limitations of our latent class models, our analyses suggest that prevalence estimates from most of the surveys reviewed are not affected by sample misclassification.
more
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant ...and breastfeeding women, children and adolescents. The Global Action Plan has five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.
more
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...und up to 3 times more often in people who had previous exposure to antiretroviral drugs. In addition, nearly half of infants newly diagnosed with HIV has HIVDR to NNRTI before initiating treatment.The high levels of observed NNRTI pretreatment HIVDR among emphasize the need to fast-track the transition to WHO-recommended dolutegravir-based ART.
more